301 results on '"Pazgier, Marzena"'
Search Results
2. Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120
3. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD
4. HIV-1 Vpu restricts Fc-mediated effector functions in vivo
5. VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entry
6. Optimization of a Piperidine CD4-Mimetic Scaffold Sensitizing HIV‑1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
7. Genetics of Exertional Heat Illness: Revealing New Associations and Expanding Heterogeneity.
8. Human Enteric α-Defensin 5 Promotes Shigella Infection by Enhancing Bacterial Adhesion and Invasion
9. Immune response profiles from humans experimentally exposed to Phlebotomus duboscqi bites
10. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
11. Defining genetic diversity of rhesus macaque Fcγ receptors with long-read RNA sequencing
12. Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site
13. Piperidine CD4-Mimetic Compounds Expose Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC
14. Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates
15. Mouse α-Defensins: Structural and Functional Analysis of the 17 Cryptdin Isoforms Identified from a Single Jejunal Crypt
16. CD4 mimetics sensitize HIV-1-infected cells to ADCC
17. Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2
18. Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques
19. The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.
20. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
21. Bma-LAD-2, an Intestinal Cell Adhesion Protein, as a Potential Therapeutic Target for Lymphatic Filariasis
22. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding
23. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19
24. D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms
25. Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX
26. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
27. Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s
28. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
29. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells
30. Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2
31. HIV-1 Envelope Glycoprotein Cell Surface Localization Is Associated with Antibody-Induced Internalization
32. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
33. Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions
34. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer
35. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
36. Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir
37. Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal Efficacy
38. Erratum for Tolbert et al., “Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial”
39. Additional file 1 of Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site
40. Studies of the Biological Properties of Human β-Defensin 1
41. Stabilizing the HIV-1 Envelope Glycoprotein State 2A Conformation
42. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
43. Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice
44. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial
45. The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site
46. Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells
47. Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor Binding
48. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
49. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects
50. A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.